Objectives: Substance use may influence study results in human subjects research. This study aims to report the concordance between self-report and biochemical assessments of substance use and test the effect of methods to reduce false reports of abstinence in trauma-exposed women participating in a research study.
| INTRODUCTION
Substance use is important to assess in psychological studies where use could affect outcomes. Past and current use, as well as the timing of recent use or the presence of withdrawal, can substantially impact a range of neurobiological, physiological, cognitive, emotional, and behavioral measures (American Psychiatric Association, 2013; Bonnet & Preuss, 2017; Evans & Cahill, 2016; Fernández-Serrano, Pérez-García, & Verdejo-García, 2011) . Substance use is common in the United States, with 10% of the U.S. adult population reporting past month illicit drug use and 56% reporting past month alcohol use (Substance Abuse and Mental Health Services Administration, 2016) .
For this reason, any research study including outcomes potentially impacted by substance use or withdrawal may benefit from rigorous substance use assessment.
Use of psychoactive substances can affect performance on a range of cognitive measures, including measures of episodic memory (cannabis, methamphetamine, 3,4-methylenedioxy-methamphetamine [MDMA], opioids, and alcohol), impulsivity (methamphetamine, MDMA, and alcohol), reasoning (heroin and alcohol), processing speed (cannabis and alcohol), cognitive flexibility (alcohol), and verbal fluency (MDMA; Fernández-Serrano et al., 2011) . Assessment of substance use is also essential to the integrity of neurobiology research (Rasmusson et al., 2017; Rasmusson, Vythilingam, & Morgan 3rd., 2003) . Acute substance use may also affect clinical trial outcomes including treatment response and dropout (Baker et al., 2007; Mazza et al., 2009) . Thus, methods to accurately measure and disincentivize substance use misreporting in clinical research studies are needed. In the current study, we report rates of discordance between self-report and biochemical assessments of substance use in a study of trauma-exposed women. The study also examined the effectiveness of methods developed to disincentivize misreporting of abstinence. Specifically, we modified the telephone prescreening script to inform participants that they would not qualify for the study or be compensated at the first in-person screening evaluation if biochemical tests for substance use were positive. We hypothesized that this telephone prescreening modification would reduce the number of participants testing positive for substances at the in-person screening evaluation. We also hypothesized that this modification would increase the rate of "no shows" and cancellations for the in-person screening evaluation by participants who misreported substance abstinence during the telephone prescreening.
| METHOD

| Design
The current study used a pre-post design (i.e., Phases 1 and 2) to examine the effectiveness of methods to reduce false reports of substance abstinence during eligibility assessment for a larger study (Nillni et al., 2015; Pineles, Blumenthal, et al., 2016; .
| Sample
One hundred sixty women (aged 18-55 years) who had experienced a Diagnostic and Statistical Manual of Mental Disorders-IV PTSD Criterion A traumatic event were included in this study (n = 114 in Phase 1 and n = 46 in Phase 2; mean age 34.63 [standard deviation = 9.91]; 38% Caucasian, 38% African American, and 24.4% of other races).
The most frequently reported "worst" traumatic events experienced included sexual trauma (24%), unexpected and sudden death of a loved one (13%), and serious motor vehicle accident (8%). Exclusion criteria included substances and medications that would disrupt the menstrual cycle or affect measures of stress hormones, as these were main aims of the larger study. This included past 30-day drug use or heavy alcohol use (defined as drinking four or more drinks on a single occasion at least twice a week), current infectious illnesses, history of organic brain disorder, schizophrenia, use of medications in the past 4 weeks, with very few exceptions (e.g., steroid inhaler), irregular menstrual cycle, oral contraceptive use, and perimenopausal or postmenopausal status.
| Procedure
Study procedures were approved by the VA Boston Healthcare System Institutional Review Board (Protocol # 2107). Women who had experienced a traumatic event were recruited via flyers and online advertisements for a study of changes in physiology across the menstrual cycle. Flow charts of participants for Phases 1 and 2 of the study and reasons for study exclusion are presented in Figure 1. 
| Phase 1
Interested women contacted the laboratory to indicate interest in the study. During a subsequent telephone prescreening session, women were asked about tobacco use ("Do you smoke? How much?"), alcohol use ("How often do you drink alcohol? And how much do you drink, on average, on the days that you drink?"), and substance use ("What drugs do you take? How often?"). Callers were informed that a urine drug test and an alcohol breathalyzer test would be performed at the in-person screening evaluation. Although they were not explicitly informed that drug and alcohol use was exclusionary, potentially eligible callers were asked to agree to abstain from alcohol and drug use during the study. Those who passed the telephone prescreen were reminded of this request 24 hr before the in-person screening evaluation.
At the in-person screening evaluation, after completion of written informed consent, urine toxicology tests, alcohol breathalyzer tests, and self-report assessments of substance use, depression, anxiety, and PTSD were performed. Regardless of eligibility for the remainder of the study, Phase 1 participants were compensated $50 for the inperson screening evaluation.
| Phase 2
Telephone prescreening methods were altered approximately 2/3 of the way through recruitment due to the high number of Phase 1 participants who tested positive for substances on urine testing despite selfreporting abstinence on the telephone prescreen (see Section 3). As in Phase 1, interested women completed a telephone prescreening session. In contrast to Phase 1 procedures, Phase 2 callers were explicitly informed that substance use would result in exclusion from the study.
To disincentivize false reports of abstinence, callers were informed that abstinence would be biochemically verified and that those testing positive for substance use at the in-person evaluation would not be paid for the visit. Specifically, the following statements were added to the beginning and end of the phone prescreen, respectively: (for example, cocaine, heroin, opiates, marijuana, benzodiazepines, antipsychotics, antidepressants, sedatives, stimulants, etc.) , or any adulteration materials (for example, bleach, peroxide, water, etc.) , you will be deemed ineligible for study participation and you will not be able to continue in the study; nor will you be compensated for the visit.
If you test positive for any legal or illegal drugs
What drugs do you take? Again, it should be noted that if you test positive for drugs at any point you will be ineligible for the study and you will not be compensated."
Those who passed the telephone prescreen were invited for an in-person evaluation (n = 46 attended). As in Phase 1, participants provided written informed consent and completed urine toxicology and alcohol breathalyzer tests and self-report assessments. Participants testing positive for drugs or alcohol on urine toxicology or breathalyzer tests were excluded from the study prior to completing the self-report assessments. We did not request that participants who tested positive for drugs or alcohol complete self-report assessments because they were not paid for the study visit and thus would not be compensated for the time required to complete the assessments. Those who tested negative for substance use on self-report and biochemical measures were paid $50 for the screening visit.
| Assessment of substance use
Participants completed a self-report assessment of substance use ("Please list all medications, drugs, and alcohol you used within the past week and the past 24 hours."; "How many cigarettes did you smoke in the last 24 hours? How many cigarettes do you smoke each day?"). The urine toxicology test detects tetrahydrocannabinol, cocaine, opiates, methamphetamine, oxycodone, and benzodiazepines. The length of time for which drug use is detectable by this test varies by substance. The shortest length of time was 1-3 days (analgesics and opiates); the longest was 30 days (long-term marijuana use and phencyclidine). Alcohol use was verified using an alcohol breathalyzer test (Alco-Sensor IV, Intoximeters, Inc.). Nicotine use was verified by a urine cotinine test (current use >200 ng/ml; Reditest; Redwood Toxicology, Santa Rosa, CA, USA; cotinine is detectable in urine for approximately 3 days after smoking).
| Additional study measures
The Beck depression inventory-II (Beck, Steer, & Brown, 1996) The PTSD Checklist (Weathers, Litz, Herman, Huska, & Keane, 1993 ) is a 17-item self-report measure of PTSD symptom severity With regard to nicotine use, which was not an exclusion criterion for the study, 30 (26%) endorsed smoking in the past 24 hr in Phase 1. Of those, 25 (22% of the total sample) tested positive for cotinine
and 5 (4%) tested negative for cotinine. In addition, 11 (10%) denied using cigarettes but tested positive for cotinine. With regard to concordance between self-report and biochemical assessment, of the 41 people who tested positive for nicotine, 25 (61%) self-reported cigarette smoking and tested positive for cotinine; 5 (12%) selfreported smoking, but their cotinine assessment was negative; and 11 (27%) denied smoking but tested positive for cotinine. In Phase 2, 4 (9%) endorsed smoking and tested positive for cotinine, 0 endorsed smoking and tested negative for cotinine, and 3 (7%) denied smoking but tested positive for cotinine.
As an exploratory aim, we examined whether the demographic and psychosocial characteristics of Phase 1 participants who reported abstinence from drugs (n = 104) differed as a function of their urine drug test (i.e., positive or negative; see Table 1 ). Within this subsample, a positive urinalysis test was associated with self-identification as a cigarette user, χ 2 = 3.88, df = 1, p = .049, as well as with using more cigarettes per day, F(1, 100) = 7.22, p = .008. Among the 13 Phase 1 participants who reported substance abstinence but had a positive urine toxicology tests, 5 (45%) also reported abstinence from cigarettes but had a positive urine cotinine test. Urine drug test results 
| DISCUSSION
The primary aim of the current study was to examine the frequency of false abstinence reporting and inconsistency across self-report and biochemical assessments of drug and alcohol use in a research study of trauma-exposed women. The study also tested the effect of methodological procedures implemented to decrease substance use at screening evaluations (an exclusion criterion) and false reports of abstinence. In Phase 1 of the study, 21% of participants had a positive substance use assessment (either self-reported or via urine toxicology test) during the initial intake appointment. All participants selfreported drug and alcohol abstinence during the telephone prescreen and had agreed to remain abstinent during the study. Thus, a significant minority of participants either misrepresented their drug use at the prescreen and/or did not comply with study requirements to maintain abstinence between the prescreen and the in-person evaluation (see Section 3).
Results also revealed that use of self-report and biochemical assessments captured substance use among different participants.
Among Phase 1 participants who tested positive for substance use and completed self-report measures, only 24% were positive on both the self-report and biochemical assessments. More than half (62%) tested positive on the biochemical assessment but denied substance use in the past week. An additional 14% reported substance use in the past week but did not test positive on the urinalysis or breathalyzer tests. With regard to nicotine use, of those in the Phase 1 sample who tested positive for smoking on self-report or urine cotinine tests, 61%
tested positive on both self-report and biochemical assessment; 12%
self-reported smoking, but it was not detectible on the urine cotinine test; and 27% self-reported not smoking but had a positive urine cotinine test. It is important to note that some substances are more readily detectable on urine drug and alcohol breathalyzer testing due to longer half-lives (e.g., marijuana). In addition, use of some other substances was not assessed (e.g., K2 and spice). People who denied cigarette use on self-reports could have been using other forms of nicotine or tobacco. Estimates of drug and alcohol use by biochemical measures are, therefore, a conservative estimate of drug use in this sample. Given the discrepant findings between methods of substance use testing, we recommend a multimethod approach to obtain as accurate an assessment of substance use as possible.
It is not surprising that many participants in this study had recently used substances given previous research demonstrating the high prevalence of substance abuse in trauma-exposed populations (Roberts et al., 2016 ) and the high rates of substance use in the general population (Substance Abuse and Mental Health Services Administration, 2016). Findings are also consistent with research showing significant discordance between self-report and biochemical assessments of substance use in other populations (Decker et al., 2014; Haller et al., 2010; Hilario et al., 2015; Wish et al., 1997; Zatzick et al., 2012) .
Although this study demonstrated that the majority of participants accurately reported abstinence during the telephone prescreen, careful in-person assessment and biochemical verification of substance use is needed to reveal the substantial minority of participants who misreport abstinence. As previously discussed, it is important to the integrity of many research studies to know the substance use status of participants, given that chronic or episodic drug or alcohol use may affect many types of study outcomes (Fernández-Serrano et al., 2011) .
Although the current study focused on trauma-exposed populations, the method for discouraging false reports of abstinence is nevertheless likely to be broadly applicable to all research studies that could be inadvertently confounded by undetected substance use. In studies wherein substance use is exclusionary, use of such methods will likely increase Note. Questions regarding age, race, veteran status, tobacco use, and alcohol use were asked during a telephone prescreen; psychological symptom scores were obtained during the in-person appointment using the Beck depression inventory (depression symptoms), the State Trait Anxiety Inventory (anxiety symptoms), and the post-traumatic stress disorder (PTSD) Checklist (PTSD symptoms). Drinks per month was calculated based on participants' answers to two demographic questions: "How many days did you drink this past month? How many drinks did you have on average on days that you drank alcohol?" SD = standard deviation; bold font indicates statistical significance and the α = .05 level the appropriate exclusion of participants using substances; when substance use is not exclusionary, results of the multimodal assessment of substance use employed (self-report plus biological verification) can be taken into account when interpreting the study data.
In the current study, informing participants about our intention to biochemically verify abstinence and disqualify participants with positive tests or signs of sample adulteration (Phase 2) significantly decreased false reports of substance abstinence. Contrary to our hypothesis, this methodological approach had no effect on scheduled in-person evaluation attendance, indicating that it led either to greater honesty during the telephone prescreen or to opting out before the inperson evaluation was scheduled. This explanation is supported by a slight increase in rates of substance use reporting on the telephone prescreen in Phase 2 (from 1% to 5% of prescreen callers reporting substance use; Figure 1) . It is also possible that these methods increased the motivation of potential participants to avoid using substances in order to qualify.
Participants whose substance abstinence was not confirmed by biochemical tests did not differ from those whose abstinence was confirmed on self-reported age, race, alcohol use, veteran status, depression, PTSD, or anxiety. Individuals who denied substance use, but tested positive on urine toxicology tests, were more likely to report smoking cigarettes and reported using more cigarettes per day. Tobacco use is highly comorbid with other SUDs (Donald, Chartrand, & Bolton, 2013) . In addition, we found that several participants who misreported substance abstinence also had cotinine tests positive for tobacco use despite denying cigarette use. It is possible that these participants were using other noncigarette forms of tobacco, but it is also possible that they believed that all substance use was exclusionary and misreported all substance use in attempt to qualify for the study. Other traits (such as including infrequent use patterns, concerns regarding social desirability, or financial motives)
not assessed in the current research may have also affected substance use reporting.
Study results should be interpreted with several limitations in mind. As discussed above, the urine drug tests included assessments of many, but not all, substances, and the substances assessed had different half-lives. Moreover, because the sample was small and only a subset of participants tested positive for drug or alcohol use, some of our analyses were likely underpowered; replication of findings is encouraged. Finally, this was not an epidemiological sample: The study only examined substance use reporting among trauma-exposed women, with regular menstrual cycles, not taking medications or In conclusion, many clinical research studies would benefit from collecting data on substance use to increase our knowledge of disease process, comorbidities, and treatment success. The current study demonstrated that a substantial minority of trauma-exposed participants misrepresented their drug or alcohol use when screened for participation in a research study. Careful assessment of substance use including self-report and biochemical verification is therefore essential when the research being conducted could be compromised by current drug or alcohol use. In addition, the methods investigated in this study appeared to substantially disincentivize false reporting of substance use and may have encouraged compliance with the study proscription against substance use.
